Replies to post #238506 on Biotech Values

[DewDiligence]

ELEV +16% on FDA Fast Track designation:

https://www.prnewswire.com/news-releases/elevation-oncology-announces-fda-fast-track-designation-granted-to-seribantumab-for-the-tumor-agnostic-treatment-of-solid-tumors-harboring-nrg1-gene-fusions-301554642.html

Even after today's pop, the share price is down 75% from its 2021 IPO.